8 Jefferies Group Neurocrine Biosciences Trades
Jefferies Group acquired 4.5 Thousand Neurocrine Biosciences shares worth $521 Thousand. That's 0.01% of their equity portfolio (709th largest holding). The first Neurocrine Biosciences trade was made in Q4 2022. Since then Jefferies Group bought shares two more times and sold shares on five occasions. The investor's estimated purchase price is $571 Thousand, resulting in a loss of 8.9%.
News about Neurocrine Biosciences, Inc. and Jefferies Group
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
Tokyo, Japan and Cambridge, UK, 12 September 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), has been notified by its partner Neurocrine Bioscienc...
FDA Greenlights Expanded Use Of Neurocrine Biosciences'' Ingrezza: Analysts Weigh In Depression Warning
The FDA approved Neurocrine Biosciences Inc''s (NASDAQ: NBIX ) Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated with Huntin...
Sosei Heptares’ Partner Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia
TOKYO and CAMBRIDGE, United Kingdom, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in G protein-coup...
Neurocrine Biosciences Dumpster-Dives To Accelerate Its International Business Development
Neurocrine is acquiring beaten-down Diurnal Group for $57M to accelerate its ex-U.S. business development. Find out what this means for investors in NBIX stock.